Ocular Therapeutix Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Ocular Therapeutix ha aumentado sus beneficios a una tasa media anual de 4.2%, mientras que los beneficios de la industria de Pharmaceuticals han experimentado un crecimiento anual de 1.7%. Los ingresos han ido creciendo a una tasa media de 47.5% al año.

Información clave

3.0%

Tasa de crecimiento de los beneficios

18.8%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals	6.0%
Tasa de crecimiento de los ingresos	43.5%
Rentabilidad financiera	-28.3%
Margen neto	-192.6%
Última actualización de beneficios	31 Mar 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Optimistic Investors Push Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Up 31% But Growth Is Lacking

Jan 09

Is Ocular Therapeutix (NASDAQ:OCUL) Using Too Much Debt?

Oct 15

Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load?

Jun 30

Analysts Just Slashed Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Numbers

Mar 08

Is Ocular Therapeutix (NASDAQ:OCUL) Using Debt In A Risky Way?

Feb 11

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Analysts Are More Bearish Than They Used To Be

Nov 16

Despite Lacking Profits Ocular Therapeutix (NASDAQ:OCUL) Seems To Be On Top Of Its Debt

Sep 09

Ocular Therapeutix: Trading Ahead Of An Underappreciated Catalyst Event

Aug 15

Some Analysts Just Cut Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) Estimates

May 13

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Ocular Therapeutix. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGM:OCUL Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Mar 24	60	-115	79	0
31 Dec 23	58	-81	74	0
30 Sep 23	58	-67	76	0
30 Jun 23	55	-91	77	0
31 Mar 23	52	-89	75	0
31 Dec 22	51	-71	72	0
30 Sep 22	50	-59	70	0
30 Jun 22	50	-33	69	0
31 Mar 22	49	-22	68	0
31 Dec 21	44	-7	67	0
30 Sep 21	39	-88	64	0
30 Jun 21	32	-103	59	0
31 Mar 21	22	-131	53	0
31 Dec 20	17	-156	49	0
30 Sep 20	12	-96	49	0
30 Jun 20	7	-103	49	0
31 Mar 20	6	-91	50	0
31 Dec 19	4	-86	47	0
30 Sep 19	2	-78	41	0
30 Jun 19	2	-74	34	0
31 Mar 19	2	-63	27	0
31 Dec 18	2	-60	24	0
30 Sep 18	2	-56	20	0
30 Jun 18	2	-56	22	0
31 Mar 18	2	-61	27	0
31 Dec 17	2	-63	31	0
30 Sep 17	2	-63	33	0
30 Jun 17	2	-57	29	0
31 Mar 17	2	-50	23	0
31 Dec 16	2	-45	18	0
30 Sep 16	2	-43	16	0
30 Jun 16	2	-44	15	0
31 Mar 16	2	-43	14	0
31 Dec 15	2	-40	13	0
30 Sep 15	2	-37	12	0
30 Jun 15	2	-33	11	0
31 Mar 15	1	-29	10	0
31 Dec 14	1	-29	9	0
30 Sep 14	0	-24	7	-8
30 Jun 14	0	-20	5	-5
31 Mar 14	0	-17	4	-2

Ingresos de calidad: OCUL actualmente no es rentable.

Margen de beneficios creciente: OCUL actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: OCUL no es rentable, pero ha reducido pérdidas en los últimos 5 años a un ritmo de 4.2% por año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de OCUL en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: OCUL no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Pharmaceuticals (-6.8%).

Rentabilidad financiera

Alta ROE: OCUL tiene una rentabilidad financiera negativa (-88.59%), ya que actualmente no es rentable.

Ocular Therapeutix Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Ocular Therapeutix, Inc. to Report Q1, 2024 Results on May 07, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Ocular Therapeutix, Inc. to Report Q4, 2023 Results on Mar 11, 2024

Third quarter 2023 earnings: EPS exceeds analyst expectations

Ocular Therapeutix, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Recent updates

Consensus EPS estimates fall by 23%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Ocular Therapeutix, Inc. to Report Q1, 2024 Results on May 07, 2024

Ocular Therapeutix, Inc., Annual General Meeting, Jun 12, 2024

Ocular Therapeutix, Inc. Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy

Ocular Therapeutix, Inc. Announces CEO Changes

Ocular Therapeutix, Inc. Announces Executive Changes

Consensus EPS estimates fall by 29%

Ocular Therapeutix, Inc. Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting

Ocular Therapeutics' Impressive Surge: A Strategic Insight

Consensus EPS estimates upgraded to US$0.67 loss, revenue downgraded

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Ocular Therapeutix, Inc. to Report Q4, 2023 Results on Mar 11, 2024

Ocular Therapeutix, Inc. Announces Management Changes

AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA

Ocular Therapeutix, Inc. Appoints Steve Meyers as Chief Commercial Officer

Ocular Therapeutix: Diabetic Retinopathy Data Q2 2024 And Wet AMD Advancement

President notifies of intention to sell stock

President recently sold US$91k worth of stock

President notifies of intention to sell stock

Ocular Therapeutix Announces FDA Agreement to Amend Special Protocol Assessment (Spa) for Pivotal Clinical Trial of Axpaxli in Wet AMD

Ocular Therapeutix Vies With Gene Therapies, Not Just Eylea, For Wet AMD

Optimistic Investors Push Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Up 31% But Growth Is Lacking

Price target decreased by 9.7% to US$11.86

Ocular Therapeutix, Inc. has completed a Follow-on Equity Offering in the amount of $100.1 million.

Ocular Therapeutix, Inc. has completed a Follow-on Equity Offering in the amount of $100.1 million.

New minor risk - Profitability

Third quarter 2023 earnings: EPS exceeds analyst expectations

Ocular Therapeutix, Inc. Provides Earnings Guidance for the Full Year 2023

Ocular Therapeutix Receives FDA Agreement Under Special Protocol Assessment (SPA) for its First Pivotal Clinical Trial of OTX-TKI in Wet AMD

AffaMed Therapeutics Announces Positive Top-Line Results from Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA® in Patients after Cataract Surgery

New minor risk - Share price stability

Ocular Therapeutix, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Is Ocular Therapeutix (NASDAQ:OCUL) Using Too Much Debt?

Ocular Therapeutix, Inc. Announces Initiation of Its First Pivotal Clinical Trial of OTX-TKI in Wet AMD

Ocular Therapeutix, Inc. Submits Request for Special Protocol Assessment to the U.S. Food and Drug Administration

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ocular Therapeutix, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Ocular Therapeutix™ Announces Appointment of Adrienne L. Graves as New Board Member

Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load?

New minor risk - Share price stability

Ocular Therapeutix, Inc. Completes Enrollment of the Helios Clinical Trial of OTX-TKI for the Treatment of Diabetic Retinopathy

Ocular Therapeutix, Inc. Present 12-Month Top-Line Data from U.S.-Based Phase 1 Clinical Trial of OTX-TKI

Ocular Therapeutix, Inc. Provides Earnings Guidance for the Year 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target increased by 7.8% to US$12.63

Analysts Just Slashed Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Numbers

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ocular Therapeutix™ Announces Interim 10-Month Data from the Ongoing U.S. Phase 1 Clinical Trial Evaluating OTX-TKI for the Treatment of Wet AMD

Is Ocular Therapeutix (NASDAQ:OCUL) Using Debt In A Risky Way?

President notifies of intention to sell stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Analysts Are More Bearish Than They Used To Be

Consensus revenue estimates fall by 13%

Insufficient new directors

Price target decreased to US$13.29

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Ocular Therapeutix, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Ocular Therapeutix, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Ocular Therapeutix, Inc. Announces Interim 7-month Data from U.S. Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD

Despite Lacking Profits Ocular Therapeutix (NASDAQ:OCUL) Seems To Be On Top Of Its Debt

Price target increased to US$15.92

Ocular Therapeutix: Trading Ahead Of An Underappreciated Catalyst Event

Ocular Therapeutix, Inc. Provides Revenue Guidance for the Full Year 2022

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Ocular Therapeutix, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Insufficient new directors

Ocular Therapeutix, Inc. Announces Executive Changes

Desglose de ingresos y gastos
Beta